# GRAIL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/grail

- Industry: Healthcare
- Headquarters: Menlo Park, US
- Website: www.grail.com
- Total disclosed funding: $1.9B
- Latest round: Series D (May 7, 2020)
- Investors on record: 25

## About

Founded in 2016 and based in California, US, GRAIL, Inc. develops a blood screening test that uses data sequencing on the genomic and molecular biology of tumors for the early detection of cancer to decrease mortality. The company was founded by Alex Aravanis, Jeff Huber, and Mostafa Ronaghi. Mr. Hans Bishop serves as the CEO of GRAIL, Inc. as of 2021. In May 2020, GRAIL, Inc. raised USD 390 million in Series D funding from new investors CPP Investment Board, TBA, and Public Sector Pension Investment Board, with participation from returning investor Illumina, Inc. In September 2020, Illumina, Inc. acquired GRAIL, Inc. for USD 8 billion.

The company develops a pan-cancer screening test designed to detect cancers at an early stage. It measures circulating nucleic acids in blood using high-intensity sequencing and population-scale clinical trials. Through its technology, the company develops its own product, Galleri, a multi-cancer early detection blood test. GRAIL is also working on technologies to assist doctors in diagnosing cancer more quickly, as well as blood-based detection for minimal residual disease and other post-diagnostic applications.

The company's revenue is generated by the sales of its pan-cancer screening test for industrial use.

## Funding rounds

- Series D, May 7, 2020, $263M — CPP Investment Board, Public Sector Pension Investment Board, Illumina, Inc., TBA Network
- Series C, May 16, 2018, $300M — Hong Shan, Hillhouse Investment, ICBC International, NextCODE, Ally Bridge Group, 6 Dimensions Capital, China Merchants Securities, Blue Pool Capital, Huangpu River Capital, CRF Investment
- Series B, Jan 11, 2018, $3M — ARCH Venture Partners, Johnson & Johnson Innovation, Bristol-Myers Squibb Company, Merck & Co., Inc., Varian Medical Systems, Inc., McKesson Ventures
- Series B, Nov 22, 2017, $238M — ARCH Venture Partners, Johnson & Johnson Innovation, Bristol-Myers Squibb Company, Merck & Co., Inc., Varian Medical Systems, Inc., McKesson Ventures
- Series B, Apr 26, 2017, $59M — ARCH Venture Partners, Johnson & Johnson Innovation, Bristol-Myers Squibb Company, Merck & Co., Inc., Varian Medical Systems, Inc., McKesson Ventures
- Series B, Feb 28, 2017, $914M — ARCH Venture Partners, Johnson & Johnson Innovation, Bristol-Myers Squibb Company, Amazon, Merck & Co., Inc., Varian Medical Systems, Inc., Tencent Holdings Limited, McKesson Ventures
- Series A, Jan 10, 2016, $120M — ARCH Venture Partners, Sutter Hill Ventures, Illumina, Inc., Bezos Expeditions, Biomatics Capital Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A
- Illumina, Inc. — Series A, Series D
- Bezos Expeditions — Series A
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Bristol-Myers Squibb Company — Series B
- Amazon (https://capitalatlas.ai/funds/amazon) — Series B
- Merck & Co., Inc. — Series B
- Varian Medical Systems, Inc. — Series B
- Tencent Holdings Limited — Series B
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series B
- Hong Shan — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- ICBC International (https://capitalatlas.ai/funds/icbc-international) — Series C
- NextCODE — Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series C
- China Merchants Securities — Series C
- Blue Pool Capital (https://capitalatlas.ai/funds/blue-pool-capital) — Series C
- Huangpu River Capital (https://capitalatlas.ai/funds/huangpu-river-capital) — Series C
- CRF Investment — Series C
- CPP Investment Board — Series D
- Public Sector Pension Investment Board — Series D
- TBA Network (https://capitalatlas.ai/funds/tba-network) — Series D